Sofjana Gushi

Dr. Sofjana Gushi

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2025 in World Academy of Sciences Journal
Verified
Journal Article
Open access
PDF file
SGSofjana Gushi
Sofjana Gushi
SDStavros P. Derdas
Stavros P. Derdas
Parkinson's disease (PD) is a disorder of the brain marked by the gradual loss of dopaminergic neurons in the substantia nigra, resulting in both motor and non‑motor symptoms. Emerging evidence indicates that the gut microbiota plays a crucial role in the development and progression of Parkinson's disease. The present review discusses the function of the gut microbiome in PD, including its makeup, interactions with the host and putative processes that relate microbial dysbiosis to neurodegeneration. In addition, the present review discusses the possibilities of diagnostic biomarkers and microbiome‑targeted therapeutics for PD. The present review synthesizes scientific literature data using a case‑control approach to provide a summary of the composition of the gut microbiota in patients with PD and healthy controls. The present review includes microbiological, clinical and biomarker data in an aim to provide a better understanding of the gut‑brain axis and its implications. Patients with PD have a lower microbial diversity and changes in certain bacterial communities, such as lower amounts of Prevotellaceae and greater amounts of Enterobacteriaceae. Dysbiosis can cause α‑synuclein misfolding, neuroinflammation and increased intestinal permeability, potentially leading to the development of PD through the gut‑brain axis. Probiotics, dietary changes and fecal microbiota transplantation all show promise for restoring microbial balance and relieving PD symptoms. Advances in metagenomics and artificial intelligence‑driven analysis help to clarify microbiome‑based therapies. The gut microbiota affects the gut‑brain axis, neuroinflammation and α‑synuclein aggregation, all of which contribute to the development of PD. Targeted microbiome therapeutics have the potential to improve illness management; however, more standardized, long‑term trials are required to determine causation and therapeutic effectiveness. The present review emphasizes the relevance of personalized techniques and modern technology in microbiome research for PD.

31 January 2026 in Children
Verified
Journal Article
Open access
PDF file
SGSofjana Gushi
Sofjana Gushi
OCOlga Chouliara
Olga Chouliara
PAParaskevi Apeiranthiti
Paraskevi Apeiranthiti
DPDimitra Panagiotidi
Dimitra Panagiotidi
Grigoris RisvasGrigoris Risvas
Grigoris Risvas
Stavros P. DerdasStavros P. Derdas
Stavros P. Derdas
Childhood malnutrition remains a pressing public health challenge in Europe, where stunting, wasting, and underweight coexist with rising rates of childhood overweight and obesity. This policy review provides a strategic roadmap for promoting healthy nutrition in early childhood by synthesizing WHO and EU guidance and proposing coordinated action across three time horizons. Short-term goals (1–3 years) include harmonizing food-based dietary guidelines, implementing universal nutrition screening in pediatric care, and strengthening breastfeeding-supportive environments. Mid-term priorities (3–7 years) focus on fiscal levers, such as sugar taxes and healthy food subsidies; reformulating children’s products; and embedding nutrition education within school curricula. Long-term strategies (7+ years) emphasize harmonized EU-wide monitoring systems, alignment of early-life nutrition with social protection policies, and sustained investment in research on the DOHaD. Through a unified, multisectoral strategy emphasizing early-life nutrition, equitable access to healthy foods, education, and robust regulation, Europe can effectively address the double burden of malnutrition and sustainably reduce childhood obesity.

1 April 2024 in Endocrine, Metabolic & Immune Disorders - Drug Targets
Verified
Journal Article
Closed access
PDF file
SGSofjana Gushi
Sofjana Gushi
VBVasileios Balis
Vasileios Balis
: Mitochondria are essential organelles for the survival of a cell because they produce energy. The cells that need more mitochondria are neurons because they perform a variety of tasks that are necessary to support brain homeostasis. The build-up of abnormal proteins in neurons, as well as their interactions with mitochondrial proteins, or MAM proteins, cause serious health issues. As a result, mitochondrial functions, such as mitophagy, are impaired, resulting in the disorders described in this review. They are also due to mtDNA mutations, which alter the heritability of diseases. The topic of disease prevention, as well as the diagnosis, requires further explanation and exploration. Finally, there are treatments that are quite promising, but more detailed research is needed.